BioWorld

Nov. 4, 2002

ImClone Submits Two Phase III Protocols For Erbitux To FDA

Amgen Among First Impacted By New Reimbursement Plan

It appears that Amgen Inc. could fall victim to a government reimbursement program that calls its anemia drug Aranesp "functionally equivalent" to a similar product, Procrit, made by Johnson & Johnson. (BioWorld Today) Read More

Ants, Winged And Wingless, Duel To The Death For Wafted Chemical Favors From Queens

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...